Internetiühendust pole — kuvatakse lehe salvestatud versioon.

Organon & Co

USUSD
← Aktsiafiltri Juurde
US:OGNLSE:0A9W

Organon & Co (LSE:0A9W) — Biotechnology: Pharmaceutical Preparations. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 2. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.

Ettevõtte Kohta

Veebileht
organon.com
Investorite Suhted
organon.com/investor-relations/
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Peakontor
Oss, United States
Tegevjuht
Joseph T. Morrissey
Töötajad
10 000
Asutatud
1923
Ringluses Olevad Aktsiad
262.61 mln seisuga 2026-07-24
1 Aasta: +1.0% · 3 aastat: +2.8% · 5 aastat: +3.6% (aktsiate splitte arvestamata)
KuupäevAktsiadMuutus
24.07.2026262.61 mln—olulisi muudatusi pole
27.04.2026262.6 mln+0.9%emissioon (lahjendamine)
17.02.2026260.32 mln+0.1%emissioon (lahjendamine)
03.11.2025259.98 mln—olulisi muudatusi pole
30.07.2025259.97 mln—olulisi muudatusi pole
25.04.2025259.96 mln+0.8%emissioon (lahjendamine)
25.02.2025257.95 mln+0.2%emissioon (lahjendamine)
25.10.2024257.54 mln+0.03%olulisi muudatusi pole
30.07.2024257.47 mln+0.1%emissioon (lahjendamine)
26.04.2024257.17 mln+0.6%emissioon (lahjendamine)
20.02.2024255.64 mln+0.01%olulisi muudatusi pole
27.10.2023255.61 mln+0.01%olulisi muudatusi pole
04.08.2023255.57 mln+0.2%emissioon (lahjendamine)
28.04.2023255.06 mln+0.3%emissioon (lahjendamine)
22.02.2023254.38 mln—olulisi muudatusi pole
Aktsiate arv ettevõtte aruannete järgi. Spliti tuvastatakse aktsiate arvu hüppe järgi täisarv korda.
Vabalt Kaubeldavad Aktsiad
242.99 mln
Turukapitalisatsioon
3.6 mld USD
Siseringi Isikud
0.46%
Institutsionaalsed Investorid
84.8%
Tegevusala (SIC)
Pharmaceutical Preparations
ISIN
US68622V1061
LEI
549300AMCKY57OK2CO56
Väljamaksesuhe
8.6%
FCF
567 mln USD
Väljamakse / FCF
3%
Võlg
8.55 mld USD
13 a FCF
Dividendistaaž
5 a
Kasum, FCF ja dividendid makstud — 12 kuu jooksul kuni 30.06.2026 (ettevõtte viimane raport).
NAV
3.83 USD · P/NAV 3.58
Bilansikuupäev30.06.2026
Varad13.2 mld USD
− Kohustused12.2 mld USD
= NAV (Ettevõtte Aktsionäride Omakapital)1.01 mld USD
− Firmaväärtus4.15 mld USD
− Immateriaalsed Varad1.11 mld USD
= Materiaalne NAV−4.26 mld USD
Aktsiad262 609 000
NAV Aktsia Kohta3.83 USD
Käegakatsutav NAV Aktsia Kohta−16.22 USD
Aktsia Hind (0A9W)13.7300 USD
P/NAV3.58
NAV Ajalugu
BilansikuupäevNAVNAV Aktsia Kohta
30.06.20261.01 mld USD3.83 USD
31.03.2026903 mln USD3.44 USD
31.12.2025752 mln USD2.89 USD
30.09.2025906 mln USD3.48 USD
30.06.2025733 mln USD2.82 USD
31.03.2025542 mln USD2.10 USD
31.12.2024472 mln USD1.83 USD
30.09.2024493 mln USD1.91 USD
Kirjeldus

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

reklaam

Börsid ja Tikkerid

BörsTikkerValuutaHindTüüp
US USA StocksOGN põhinoteeringUSD13.76 +0.15%tavalised aktsiad
LSE London Stock Exchange0A9W IOBUSD13.73 +0.07%tavalised aktsiad

Hind 3 Kuu Jooksul

3M1Y3Y5Y
tõususepäev langusepäev dividendi ex-kuupäev väljamakse kuupäevViige kursor / puudutage päeva — avamis-, sulgemis-, kõrgeim ja madalaim hind

Dividendid

Aastas LSE:0A9W: 0.08 USD (4 väljam.)

Organon & Co (0A9W) maksab dividende kvartalis. Aastas (12 kuud kuni viimase teatatud maksega): 0.08 USD aktsia kohta (maksed: 4). See on umbes 0.58% praegusest aktsiahinnast. Makseajaloo põhjal oodatakse järgmist ex-dividendi kuupäeva umbes 17.11.2026. Katkematu dividendiajalugu: 5 aastat.

Ex-KuupäevVäljamakseSumma%TüüpTikker
2026-08-142026-09-100.0200 USD0.1/0.6 %kord kvartalisLSE:0A9W
2026-05-112026-06-110.0200 USD0.2/0.6 %kord kvartalisLSE:0A9W
2026-02-232026-03-120.0200 USD0.3/1.0 %kord kvartalisLSE:0A9W
2025-11-202025-12-110.0200 USD0.3/4.6 %kord kvartalisLSE:0A9W
2025-08-152025-09-110.0200 USD0.2/6.5 %kord kvartalisLSE:0A9W
2025-05-122025-06-120.0200 USD0.2/9.7 %kord kvartalisLSE:0A9W
2025-02-212025-03-130.2800 USD1.8/7.2 %kord kvartalisLSE:0A9W
2024-11-122024-12-120.2800 USD1.5/6.0 %kord kvartalisLSE:0A9W
2024-08-162024-09-120.2800 USD1.5/6.0 %kord kvartalisLSE:0A9W
2024-05-102024-06-130.2800 USD1.5/6.0 %kord kvartalisLSE:0A9W
2024-02-232024-03-140.2800 USD1.5/6.0 %kord kvartalisLSE:0A9W
2023-11-102023-12-140.2800 USD2.4/9.8 %kord kvartalisLSE:0A9W
2023-08-17—0.2800 USD1.2/4.9 %kord kvartalisLSE:0A9W
2023-05-12—0.2800 USD1.3/5.3 %kord kvartalisLSE:0A9W
2023-02-24—0.2800 USD1.1/4.2 %kord kvartalisLSE:0A9W
2022-11-10—0.2800 USD1.2/4.7 %kord kvartalisLSE:0A9W
2022-08-12—0.2800 USD0.9/3.5 %kord kvartalisLSE:0A9W
2022-05-13—0.2800 USD0.8/2.4 %kord kvartalisLSE:0A9W
2022-02-25—0.2800 USD0.8/1.6 %kord kvartalisLSE:0A9W
2021-11-19—0.2800 USD0.9/0.9 %kord kvartalisLSE:0A9W

Suurimad Omanikud

OmanikOsalusAktsiadAruande Kuupäev
Blackrock Inc.12.21%32.06 mln2026-06-30
Pentwater Capital Manage…6.89%18.1 mln2026-06-30
iShares Trust-iShares Co…6.09%16 mln2026-08-31
Vanguard Portfolio Manag…5.76%15.13 mln2026-06-30
Vanguard Capital Managem…4.54%11.91 mln2026-06-30
State Street Corporation3.68%9.66 mln2026-06-30
VANGUARD INDEX FUNDS-Van…3.17%8.33 mln2026-06-30
VANGUARD INDEX FUNDS-Van…2.29%6.02 mln2026-06-30
Goldman Sachs Group Inc1.98%5.2 mln2026-06-30
UBS Group AG1.85%4.86 mln2026-06-30
Geode Capital Management…1.83%4.82 mln2026-06-30
Alliancebernstein L.P.1.81%4.75 mln2026-06-30
Man Group PLC1.59%4.18 mln2026-06-30
VANGUARD INDEX FUNDS-Van…1.45%3.82 mln2026-06-30
VANGUARD INDEX FUNDS-Van…1.15%3.01 mln2026-06-30
NexPoint Funds I-NexPoin…1.03%2.71 mln2026-06-30
SPDR SERIES TRUST-State…0.94%2.47 mln2026-08-31
iShares Trust-iShares S&…0.89%2.35 mln2026-08-31
SPDR SERIES TRUST-State…0.54%1.41 mln2026-08-31
Fidelity Concord Street…0.49%1.3 mln2026-07-31
ALI KEVIN (Chief Executi…≈0.11%282 7312025-05-05
WALSH MATTHEW M (Chief F…≈0.08%212 7462026-03-31
MORRISSEY JOSEPH T JR (C…≈0.05%123 1232026-03-31
STAHLER RACHEL A (Chief…≈0.04%116 1052026-03-31
FALCIONE AARON (Officer)≈0.04%101 4312026-03-31
WEAVER KIRKE (General Co…≈0.04%92 6392026-03-31
NISITA VITTORIO (Officer…≈0.03%70 6192026-03-31
KARP DANIEL (Officer)≈0.03%69 5472026-03-31
HOLZBAUR LYNETTE (Office…≈0.02%52 8502026-05-06
COX CARRIE SMITH (Office…——2025-11-12